Fluorescent fungal cells help researchers quickly identify most effective compounds
On a molecular level, you have more in common with shower curtain mold or the mushrooms on your pizza than you might think. Humans and fungi share similar proteins, a biological bond that makes curing fungal infections difficult and expensive. Current costs to treat these stubborn infections can top $50,000 per patient, and no new classes of antifungal drugs that treat systemic infections have been introduced for at least 20 years.
Now, researchers at The Ohio State University Wexner Medical Center have discovered a new compound that could be developed as an antifungal drug to treat histoplasmosis and cryptococcosis, two types of fungal infections that are naturally drug-resistant.
Generally, people with weakened immune systems are more likely to develop life-threatening fungal infections. However, the airborne fungus Histoplasma capsulatum, which causes histoplasmosis, can infect healthy people as well.
“Histoplasmosis is an unusual fungal disease because anyone can be infected, not just people with compromised immune systems. Like tuberculosis, Histoplasma infects healthy hosts, attacks their lungs, and can lie dormant in immune cells for years, later causing reactivation disease,” said Chad Rappleye, PhD, a microbiologist in the Center for Microbial Interface Biology at Ohio State’s Wexner Medical Center and in the Department of Microbial Infection and Immunity at Ohio State’s College of Medicine. “So this is an unrecognized public health threat that’s needed better treatment options for some time.”
There are an estimated 100,000 Histoplasma infections each year in the United States. Most are contained by the body’s immune system, but each year a few thousand people will develop chronic or life-threatening histoplasmosis disease requiring hospitalization and antifungal treatment. The antifungals currently used to treat the infection have undesirable toxic side effects requiring monitoring by a physician and may need to be taken for weeks or months.
“Histoplasma is particularly good at avoiding detection by the body’s immune system and surviving the immune response,” said Jessica Edwards, PhD, a postdoctoral researcher at Ohio State University.
Respiratory histoplasmosis manifests with flu-like symptoms, often making diagnosis difficult. Rappleye says people with histoplasmosis have been mistakenly diagnosed with colds, the flu, and even lung cancer. “It depends on how familiar a physician is with histoplasmosis,” he said.
Intrigued by the challenges of finding a new drug that would target the fungus without harming the human host, in 2012, Rappleye received pilot funding from Ohio State’sCenter for Clinical and Translational Science (CCTS) and the Public Health Preparedness for Infectious Diseases Program (PHPID).
Rappleye’s team searched a library of commercially-available small molecules used by other investigators to find new antivirals or anticancer drugs. They performed a high-throughput phenotypic screen of 3,600 compounds looking for agents that inhibited fungal, but not human, cells.
To speed the selection process, Rappleye and Edwards engineered Histoplasma cells with a fluorescent protein that made the cells glow red while inside of a living macrophage – the type of mammalian immune cell thatHistoplasma attacks and in which it reproduces.
As the number of fungal cells increased inside the macrophage, so did the fluorescence and consequently, the cells would glow brighter. However, when a macrophage was exposed to an active compound that prevents Histoplasma reproduction, it maintained the same level of brightness. This allowed the scientists to quickly determine efficacy and toxicity of the drug candidate in a natural environment.
“Not only were we able to visually screen thousands of compounds in just a few weeks, but we were also able to measure the compound’s impact in a real, live host cell,” said Edwards.
The Latest on: Fungal Lung Infections
- Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline on February 19, 2019 at 6:00 am
The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary ... […]
- Mucormycosis Market Size, Share, Demand, Financial Overview, Key Developments, SWOT Analysis and Forecast to 2023 on February 18, 2019 at 2:03 am
Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fu... […]
- Grandmother, 63, fights for life after catching hospital infection blamed on nesting pigeons on February 13, 2019 at 8:50 pm
A grandmother is fighting for her life after contracting a fungal lung infection at a Scots hospital where two other patients died during bacterial outbreaks linked to pigeon droppings. Mito Kaur, 63, ... […]
- Family find out gran has infection linked to pigeon droppings from Glasgow hospital website on February 13, 2019 at 2:51 am
She was diagnosed with pneumonia two days later and influenza was found in her lungs so she was given antibiotics ... for greater expertise on the infection. The family have not been told where or if ... […]
- Gift from Centennial teacher’s non-profit will advance research into non-invasive test for lung cancer on February 12, 2019 at 12:00 pm
They chose to fund “Cancer or Fungus? Avoiding Unnecessary Surgeries of Lung Nodules ... the University of Kentucky to test patients with histoplasmosis, a common lung infection in the central U.S. th... […]
via Google News and Bing News